Last reviewed · How we verify
NCT06246630
In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
NA trial testing Chemotherapy and targeted-therapy guided by organoid drug sensitivity test in Advanced Pancreatic Neuroendocrine Tumor in 20 participants. Currently enrolling.
25 December 2025
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 3 April 2024 |
| Primary completion | 25 December 2025 |
| Estimated completion | 25 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Conditions studied
- Advanced Pancreatic Neuroendocrine Tumor — all drugs for Advanced Pancreatic Neuroendocrine Tumor →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 75, any sex, with Advanced Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic neuroendocrine tumors. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735 -
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.
Taurin S, Alzahrani R, Aloraibi S, Ashi L, et al · · 2025 · cited 15× · PMID 39622151 · DOI 10.1016/j.tranon.2024.102226 -
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.
Wang Y, Zhang L, Wang LZ, Cao Y, et al · · 2025 · cited 4× · PMID 40855314 · DOI 10.1186/s12943-025-02429-0 -
Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.
Li R, Wu Y, Zheng Z, Zhou F, et al · · 2026 · cited 1× · PMID 41503026 · DOI 10.1002/mco2.70575
Verify or expand the search:
- PubMed search for NCT06246630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Trials testing the same drug.
- NCT06406660 — Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer · NA · recruiting
- NCT06406608 — Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer · NA · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06246630 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 16 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing